A Phase 3 interventional study of KLH-2109 and Placebo in Uterine Fibroids (MeSH Heading: Leiomyoma), sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-11-25.
Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Leiomyoma with a site in Japan — none open to participants now, none under way, none of them phase 3. Leiomyoma · Japan.
Among the 12 studies in Leiomyoma with a site in Japan, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2022, is one of 8 in phase 3, and was the 11th registered.
438 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.
Browse Leiomyoma studies →None of the 12 studies in Leiomyoma with a site in Japan is open now. The open studies under Leiomyoma, anywhere →
Of the 43 Leiomyoma studies recruiting now, 21 (49%) set no upper age limit and 21 (49%) stop at 75 or younger; 3 take children under 18; 9 take healthy volunteers.
This study: 20 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2022.
This study's enrollment of 89 is above the median of 66 across 306 interventional studies indexed under Leiomyoma.
Median enrollment 185 across the 10 interventional studies, 16 across the 1 observational. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 4 most frequent:
Kissei Pharmaceutical Co., Ltd. is the lead sponsor of 63 studies on the registry; 3 are open to participants now.
Kissei Pharmaceutical Co., Ltd. has 2 studies filed under Leiomyoma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Leiomyoma with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Multi-center, randomized, double-blind, parallel-group study to confirm superiority of KLH-2109 to placebo in uterine fibroids patient with menorrhagia and pain
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: KLH-2109
Drug: Placebo
Oral administration
Oral administration
Proportion of subjects with a total PBAC score of less than 10 from Week 6 to 12 after beginning of study drug administration
PBAC (pictorial blood loss assessment chart) score
Time frame: Up to 12 weeks
Proportion of women with a maximum NRS for pain score of 1 or less during 28 days before the end of study drug administration
NRS (numeric rating scale) for pain
Time frame: Up to 12 weeks
Proportion of subjects with a total PBAC score of less than 10 from Week 2 to 6 after beginning of study drug administration
PBAC (pictorial blood loss assessment chart) score
Time frame: Up to 12 weeks
Proportion of subjects with a total PBAC score of less than 10 during 6 weeks before end of study drug administration
PBAC (pictorial blood loss assessment chart) score
Time frame: Up to 12 weeks
Proportion of subjects with a maximum NRS score of 1 or less for pain symptoms every 28 days
NRS (numerical rating scale)
Time frame: Up to 12 weeks
Proportion of subjects with maximum NRS score of zero for pain symptoms during 28 days before end of study drug administration
NRS (numerical rating scale)
Time frame: Up to 12 weeks
Proportion of subjects with a maximum NRS score of zero for pain symptoms every 28 days
NRS (numerical rating scale)
Time frame: Up to 12 weeks
Average NRS score every 28 days for pain symptoms
NRS (numerical rating scale)
Time frame: Up to 12 weeks
Percentage of asymptomatic days (number of the days with NRS score of zero for pain symptoms) during 28 days before end of study drug administration
NRS (numerical rating scale)
Time frame: Up to 12 weeks
Percentage of asymptomatic days (number of the days with NRS score of zero for pain symptoms) every 28 days
NRS (numerical rating scale)
Time frame: Up to 12 weeks
Incidence of adverse events and adverse drug reactions
Adverse events and adverse drug reactions
Time frame: Up to 12 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Oct 2022 to primary completion in Feb 2024, 16 months.
Of 25 phase 3 interventional studies under Leiomyoma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 41. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linzagolix
Kissei Pharmaceutical Co., Ltd. →